Quercetin impairs *Streptococcus pneumoniae* biofilm formation by inhibiting sortase A activity

**Jianfeng Wang** | **Meng Song** | **Juan Pan** | **Xue Shen** | **Wentao Liu** | **Xueke Zhang** | **Hongen Li** | **Xuming Deng**
---|---|---|---|---|---|---|---
1Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, China  
2Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun, China  
3Tianjin International Travel Healthcare Center, Tianjin, China  
4Heilongjiang Veterinary Drug and Feed Super Vision Institute, Haerbin, China

**Abstract**

Biofilm formation mediated by sortase A (srtA) is important for bacterial colonisation and resistance to antibiotics. Thus, the inhibitor of SrtA may represent a promising agent for bacterial infection. The structure of *Streptococcus pneumoniae* D39 srtA has been characterised by crystallisation. Site-directed mutagenesis was used for the determination of the key residues for the activity of *S. pneumoniae* D39 srtA. An effective srtA inhibitor, quercetin, and its mechanism was further identified using srtA activity inhibition assay and molecular modelling. In this study, the crystal structure of *S. pneumoniae* D39 srtA has been solved and shown to contain a unique domain B. Additionally, its transpeptidase activity was evaluated in vitro. Based on the structure, we identified Cys207 as the catalytic residue, with His141 and Arg215 serving as binding sites for the peptide substrate. We found that quercetin can specifically compete with the natural substrate, leading to a significant decrease in the catalytic activity of this enzyme. In cells co-cultured with this small molecule inhibitor, NanA cannot anchor to the cell wall effectively, and biofilm formation and biomass decrease significantly. Interestingly, when we supplemented cultures with sialic acid, a crucial signal for pneumococcal colonisation and the invasion of the host in the co-culture system, biofilm loss did not occur. This result indicates that quercetin inhibits biofilm formation by affecting sialic acid production. In conclusion, the inhibition of pneumococcal srtA by the small molecule quercetin offers a novel strategy for pneumococcal preventative therapy.

**KEYWORDS**

anti-infection, biofilm, quercetin, sortase A, *Streptococcus pneumoniae*

---

**1 | INTRODUCTION**

Pneumococcal infections, including pneumonia, otitis media, meningitis, and bacteremia, cause almost 2 million deaths annually. Biofilm formation plays an important role in bacterial survival and infection. For *Streptococcus pneumoniae*, biofilm formation is necessary for pneumococcal survival, early colonisation, and resistance to antimicrobial agents. Many factors are involved in biofilm formation; neuraminidase A (NanA) is one such factor. NanA, which is conserved in all strains and cleaves sugars from the mucosal surface, supports the release of sialic acid, which has been identified as a preventable signal for pneumococcal colonisation and invasion of the host by *S. pneumoniae*. Furthermore, NanA possesses an LPETG motif at the C terminus and therefore requires...
transpeptidation by *S. pneumoniae* sortase A (Spn-srtA) for proper anchoring to the cell wall.6

Many surface proteins of Gram-positive bacteria are anchored to the cell wall envelope by srtA, which recognises the conserved LPXTG motif, where X is any amino acid.6 The thiolate group of an essential active site Cys attacks the scissile Thr-Gly bond, and two absolutely conserved residues, a His and an Arg, are located in the active site.7–9 Studies have shown that srtA from *Staphylococcus aureus*, *Bacillus anthracis*, and *Listeria monocytogenes* are directly related to bacterial adherence to host tissues.5

The *S. pneumoniae* srtA gene is widely expressed and highly conserved amongst isolated strains.10 Although *S. pneumoniae* TIGR4 has three additional putative sortase genes, srtB, srtC and srtD, these genes are absent in *S. pneumoniae* D39.11,12 Spn-srtA has been shown to play a role in nasopharyngeal colonisation in chinchilla and adhesion to human pharyngeal cells in vitro.11,12 Spn-srtA is also important for pneumonia, bacteremia, and nasopharyngeal colonisation in mouse models, and it affects intraperitoneal immunity in mouse models. Evidence also suggests that Spn-srtA is a promising candidate for a protein-based pneumococcal vaccine.10,13

Quercetin has been shown to inhibit the activity of SrtA from *Streptococcus mutans* and *Staphylococcus aureus*.14,15 Here, we found that Spn-srtA contains a domain B in addition to the domain A found in all sortases. Cys207 is the catalytic residue, and His141 and Arg215 are the binding sites for the peptide substrate. The small molecule quercetin efficiently reduced sortase activity, allowing NanA to be released into the culture. Herman-Bausier et al16 showed that *S. aureus* fibronectin binding protein A mediates cell-cell adhesion through low-affinity homophilic bonds, and we observed a similar mechanism in *S. pneumoniae*: NanA self-assembly assists pneumococcal aggregation and leads to biofilm formation. By preventing the normal anchoring of NanA, quercetin abrogated sialic acid production and bacterial aggregation and ultimately reduced pneumococcal biofilm formation. In summary, abating Spn-srtA activity and impairing pneumococcal biofilm formation seem to be a novel strategy for fighting pneumococcal infection.

2 | MATERIALS AND METHODS

2.1 | *Streptococcus pneumoniae* D39 srtA cloning, expression, and purification

The DNA sequence encoding Spn-srtA residues Val-82 to Tyr-247 (srtAΔN81) was amplified from *S. pneumoniae* D39 genomic DNA using the primers 5’-CTTGGATCCTAAATTTCTATGCCAT-3’ (forward) and 5’-ATGTTCTGAGTCTCAGAAAAATATAAAAAG-3’ (reverse). The amplified fragment was digested with *BamHI* and *Xhol* and cloned into a pGEX-6P-1 expression vector. The recombinant vector with an N-terminal GST was transformed into *Escherichia coli* BL21 (DE3) cells for overexpression of the recombinant protein.

Cultures of BL21 (DE3) harbouring the srtAΔN81-pGEX-6P-1 vector were grown at 37°C in a shaking incubator to an A600 of 0.6-0.8 in Luria-Bertani medium supplemented with ampicillin (100 mg/L). IPTG was then added to a final concentration of 0.5 mM, and the cultures were grown for a further 4 hours at 30°C prior to harvesting. Cell pellets were resuspended in phosphate buffered saline (PBS) and lysed by sonication. The lysed cells were centrifuged at 40 555 g at 4°C for 30 minutes.

The cell lysate was mixed with glutathione Sepharose beads (GE Healthcare, Uppsala, Sweden) that were pre-equilibrated with PBS for 1 hour. The unbound proteins were washed away with PBS after loading onto the column. The eluted GST-srtAΔN81 was mixed with PreScission protease at a ratio of 50:1 (w:w) in buffer A (25 mM HEPES, 100 mM NaCl, pH 7.0) and incubated at 4°C overnight to cleave the GST tag. Spn-srtAΔN81 was further purified by ion exchange chromatography on a Resource Q column (GE Healthcare). Two peaks were obtained, and both were determined to contain srtAΔN81 by SDS-PAGE. Portions of both peaks were collected and concentrated before being loaded onto a Superdex 75 gel filtration column (GE Healthcare) pre-equilibrated with buffer A. The fractions containing only Spn-srtAΔN81 were pooled and concentrated to a final concentration of 15 mg/mL and stored at −20°C.

The Spn-srtAΔN81 H141A, R215A, and C207A mutants were expressed and purified as described above for the wild-type protein.

2.2 | Crystallisation

SrtAΔN81 crystals were grown at 16°C using the hanging-drop vapour diffusion method over a reservoir of 1.8 mol/L (NH₄)₂SO₄ and 0.1 mol/L Bis-Tris (pH 6.0). Crystals were grown to full size within 4 days.

2.3 | Data collection and structure determination

Cryo-cooling was carried out by soaking the crystals in a reservoir solution containing 20% (v/v) glycerol prior to flash-cooling with liquid nitrogen. All of the diffraction data sets were collected at beam line BL1A of the Photon Factory synchrotron facility in Shanghai using a CCD detector, with a maximum resolution of ~3.3 Å. The space group of *S. pneumoniae*-srtAΔN81 crystals is I4122, with 2 protein molecules per asymmetric unit. The initial phases were obtained with the molecular replacement method using the program Phaser v2.1,17 and the *S. aureus*-srtAΔN59 crystal structure was used as the search model (Protein Data Bank [PDB] ID: 1T2P). Manual model building and refinement were performed with COOT18 and PHE-NIX19 using a rigid body, TLS parameters and individual B-factor refinement. Solvent molecules were located based on stereochemically reasonable peaks in the σₐ-weighted 2Fo-Fc difference electron density map. The quality of the final refined model was verified using the program PROCHECK.20 Final refinement statistics are summarised in Table 1. Structure figures were displayed using PyMOL.21

2.4 | Site-directed mutagenesis

Site-directed mutagenesis of srtAΔN81 was performed to produce the H141A, R215A and C207A mutants using the QuickChange...
2.6 | Spn-srtA<sub>ΔNB1</sub> activity inhibition assay

Quercetin was prepared at different concentrations (0, 12.5, 25, 50, 100, and 200 μM) in DMSO and mixed with Spn-srtA<sub>ΔNB1</sub> for 15 minutes at 37°C. Samples were then analysed fluorometrically using the protocol described above. Blank samples (negative controls) contained all of the above except wild-type Spn-srtA.

2.7 | Bacterial cultures

*Streptococcus pneumoniae* strain D39 was grown in Todd-Hewitt broth (THB) + 2% yeast extract (THY media). Bacteria stored in glycerol at −80°C were thawed at room temperature and inoculated into fresh liquid THY medium. Bacteria were grown overnight to stationary phase at 37°C in a 5% CO<sub>2</sub> incubator.

2.8 | *Streptococcus pneumoniae* biofilm formation and biomass measurements

Mid-log-phase cell suspensions (1 × 10<sup>8</sup> CFU/mL) were diluted 1:100 with fresh sterile THY media, and 1 mL aliquots were added in triplicate to the wells of a 24-well flat-bottom polystyrene microtitre plate with different concentrations of quercetin (0, 12.5, 25, 50, 100, and 200 μM). The plate was incubated statically for 15-18 hours at 37°C, under 5% CO<sub>2</sub>. The OD<sub>570</sub> was measured to determine the levels of bacterial growth. After incubation, the medium was aspirated, and the plates were gently washed three times with 1 mL of sterile PBS. Plates were then air-dried and stained for 1 hour with 400 μL of 0.1% crystal violet (CV). Excess stain was decanted, and plates were washed three times with sterile distilled water. Plates were then allowed to dry, and the bound CV was dissolved in 200 μL of 95% ethanol. The OD<sub>570</sub> was measured using a microplate reader. The data represent the average values of three replicates.

Biofilm biomass was quantified in terms of colony forming units (CFUs). *Streptococcus pneumoniae* biofilms were grown and washed as described above. Biofilm disaggregation was performed by gentle pipetting and slow vortexing. The biofilm bacteria were serially diluted, cultured on blood agar plates, and CFUs were counted.

2.9 | Western blotting of pneumolysin

The bacteria were grown in the presence of different concentrations of quercetin (0, 12.5, 25, 50, and 100 μM) as described above. Bacterial pellets were lysed and heated. Equal amounts of protein were separated by 12% SDS-PAGE and transferred to polyvinylidene
fluoride membranes. The membranes were blocked, incubated with a monoclonal antibody against pneumolysin (1:1000; Abcam, Cambridge, UK), probed with HRP-conjugated secondary anti-mouse antibodies (1:2000; Proteintech, Chicago, IL, USA), and developed with ECL reagent (Thermo Scientific, Rockford, IL, USA). The protein bands were visualised using a Tanon-4200 imager.

2.10 | Supplementation of sialic acid in the quercetin and S. pneumoniae co-culture system

Streptococcus pneumoniae D39 was grown in a 24-well polystyrene microtitre plate with different concentrations of quercetin (0 or 100 μM) and sialic acid (0 or 3.2 mM) as described above. The biofilm was stained with 0.1% CV and quantified as described above.

2.11 | Molecular modelling

In this work, the initial srtA structure was derived from the crystal structure (Figure 1). The starting structure of the ligand/srtA complex for the molecular dynamics (MD) simulation was obtained using AutoDock 4 based on the standard docking procedure for a rigid protein and a flexible ligand. Then, the MD simulation was carried out for the complex using detailed computational biological processes described in previous reports.

2.12 | Statistical analysis

Data were assessed using independent-sample Student's t test (n ≥ 3). Analyses were performed using Graph Pad Prism (Graph Pad Software Inc., San Diego, CA, USA). Data are presented as mean ± SD. The significance levels of P < 0.05 and P < 0.01 between group means are indicated in the figures.

3 | Results

3.1 | The structure of S. pneumoniae D39 srtA

The Spn-srtAΔN81 structure contains 4 α-helix and 7 β-sheet folds and contains two domains (domain A and domain B) that are unique to sortases and whose structures have been previously described (Figure 1). Despite sharing 28% or even 56% sequence identity (Figure 2D), the overall structure of Spn-srtAΔN81 is differed substantially from that of S. aureus-srtAΔN59 (Sa-srtAΔN59) and S. pyogenes-srtAΔN81 (Sp-srtAΔN81), which possess only domain A (Figure 2C). Sa-srtAΔN59 and Sp-srtAΔN81 can be overlaid on Spn-srtAΔN81 with an RMSD of 1.8 Å (87 equivalent Cα atoms) (Figure 2A) and 23.6 Å (149 equivalent Cα atoms) (Figure 2B), respectively. The structure of Spn-srtAΔN81 contains a huge hole formed by domain B.

3.2 | Substrate recognition assay

To gain further insights into the interaction between Spn-srtAΔN81 and its substrates and to analyse its cleavage specificity, an oligopeptide substrate was modelled in the substrate binding site in silico. The structure of Sa-srtA in complex with its LPETG substrate (PDB entry: 1T2W) was used as the basis for the initial modelling. As shown in Figure 3A, the results indicated that the two “hand” residues His141 and Arg215 catch the LPETG peptide, which is then cleaved by the active site residue Cys207.

3.3 | His141 and Arg215 are the binding sites and Cys207 is the catalytic residue for the peptide substrate

Previous studies of Sa-srtA and Sp-srtA identified Cys208, His142, and Arg216 as the key catalytic residues (Figure 3B). We found that although the Spn-srtA structure differs from those of Sa-srtA and Sp-srtA, the active residues of Spn-srtA are also His141, Cys207, and Arg215. Spn-srtA loses its transpeptidation activity if these three amino acids are mutated (Figure 3C).

3.4 | Quercetin inhibits S. pneumoniae srtA activity

The activity of purified Spn-srtAΔN81 was measured in the presence of different concentrations of quercetin (Figure 4A) (0, 12.5, 25, 50, 100, and 200 μM), and quercetin was discovered to significantly inhibit Spn-srtAΔN81 (P < 0.01) catalytic activity in a dose-dependent manner (Figure 4B).

3.5 | Quercetin impairs pneumococcal biofilm formation and reduces biomass

Parker and coworkers demonstrated that NanA is involved in biofilm formation and showed that a NanA mutant has significantly reduced...
activity compared to the wild-type in S. pneumoniae D39. Thus, we examined whether a small molecule inhibitor could prevent pneumococcal biofilm formation. Indeed, pneumococcal biofilm formation was reduced with increasing quercetin concentration. The reduction in biofilm formation was indicated by the reduced intensity of CV staining (Figure 5A).Biofilm formation with 12.5 μM quercetin was significantly (P < 0.01) reduced compared to biofilm formation without quercetin (Figure 5B). The biofilm biomass was measured by counting CFU. Compared to biofilm growth in the absence of quercetin, biofilms grown in the presence of quercetin concentrations ≥12.5 μM displayed significantly reduced biomass (P < 0.05; Figure 5C). Additionally, Shak et al previously revealed an unrecognised role for pneumolysin in biofilm formation. We further tested the effect of quercetin on pneumolysin expression via western blotting and found that quercetin had no effect on pneumolysin expression (Figure 4C). Thus, the loss of pneumococcal biofilm formation caused by quercetin was exclusively due to the inhibition of Spn-srtA activity.

3.6 | Sialic acid reverses quercetin-mediated inhibition for the pneumococcal biofilm formation

Trappetti et al found that sialic acid could reverse the inhibition of biofilm formation caused by mutating NanA. Our results revealed that sialic acid treatment similarly restored biofilm formation following the disruption of pneumococcal srtA activity. We added 3.2 mM sialic acid and 50 μM quercetin to a bacterial co-culture system and found that biofilm formation by S. pneumoniae D39 recovered to the same level as that in the positive control (Figure 5D). In agreement with this result, the inhibitory effect of quercetin (50 μM) on biofilm growth was reduced in the presence of 3.2 mM sialic acid (Figure 5E).
The biofilm biomass was measured by counting CFU. Compared to biofilm growth in the absence of quercetin, biofilms grown in the presence of quercetin concentrations $\geq 12.5\ \mu M$ displayed significantly reduced biomass.

### 3.7 Molecular modelling

In this work, we initially obtained a crystal structure of the srtA dimer. However, the biologically active form of srtA is a monomer in vivo. To explore the structural features of srtA, MD simulations were performed using the crystal structure of srtA as the initial structure. During a 200-ns MD simulation, the 3-D structure of monomeric srtA was first equilibrated with the solute (Figure 6A-C). This was further used to model the molecular docking of quercetin. The data showed that mutating either Leu113 or Leu118 (Figure 6D) significantly reduced the inhibitory activity of quercetin towards Spn-srtA, indicating that the inhibitor occupies the channel where the substrate binds to the protein, causing steric hindrance between the substrate and Spn-srtA (Figure 6E).

### 4 Discussion

Bacterial pathogens have evolved numerous defence mechanisms against antibiotics that have traditionally targeted key components of the bacterial growth cycle and conferred evolutionary pressure on targeted bacteria. In 1985, Liu and Tomasz identified five clinical isolates of *S. pneumoniae* in South Africa that displayed tolerance to penicillin. In addition, Vancomycin-tolerant *S. pneumoniae* has recently been identified in several countries. There are now fewer effective antibiotics that are available for fighting the pneumococcal infection.

Fortunately, the emergence of new anti-infective strategies that target the bacterial infection process has begun to ease this problem.

---

**FIGURE 3** Substrate binding mode and the activity of Spn-srtA$_{\Delta N81}$ mutants. A. The binding mode of Spn-srtA and the natural substrate peptide LPETG. B. The positions of His141, Cys207, and Arg215 in *Streptococcus pneumoniae* D39 srtA$_{\Delta N81}$. C. Purified mutant protein used to determine Spn-srtA$_{\Delta N81}$ activity compared to the wild-type enzyme (WT). Error bars are $\pm$ SD. $n=5$. ** indicates $P<0.01$ compared with the wild-type srtA$_{\Delta N81}$

**FIGURE 4** The inhibitory effect of quercetin on Spn-srtA and western blotting of pneumolysin expression. A. The structure of quercetin. B. Inhibition of Spn-SrtA activity in the presence of various concentrations of quercetin (0-100 $\mu M$). C. Western blot analysis of pneumolysin expression in *S. pneumonia* D39 cultured with different concentrations of quercetin (0-100 $\mu M$). The samples treated with 0 $\mu M$ quercetin were exposed to an equal volume of DMSO. Error bars are $\pm$ SD. $n=5$. * indicates $P<0.05$ and ** indicates $P<0.01$ compared with the quercetin-free sample.
to some extent. For example, baicalin is able to protect mice from S. aureus pneumonia by inhibiting the cytolytic activity of α-hemolysin, and fisetin has also proven effective in attenuating L. monocytogenes infection by targeting listeriolysin O. The sortase mutants for S. aureus and Streptococcus suis were previously identified to interfere with the display of surface proteins and affects pathogenesis in animals. Therefore, srtA has received considerable attention as a target for fighting bacterial infection. Many srtA structures have been elucidated, and molecular inhibitors have been found or designed for Gram-positive infections.

In this study, we present the crystal structure of Spn-srtA composed of a domain A and a domain B, which differs from the
structure of srtA in *S. aureus* and *S. pyogenes*. However, consistent with other reports srtA, His141, Cys207, and Arg215 are still the active residues for Spn-srtA activity. Mutation of any of these three amino acids results in significant loss of srtA transpeptidation activity. Additionally, our findings provide a probable explanation regarding why *S. pneumoniae* D39 only expresses srtA, whereas srtA, sortase B, sortase C, and sortase D coexist in *S. aureus* and *S. pyogenes*. The three active sites of Spn-srtA, His141, Cys207, and Arg215, are located on loops, which are more flexible than α-helices and β-sheets. Therefore, the His-Cys, Cys-Arg, and Arg-His distances are 13 Å, 7.2 Å and 18.3 Å, respectively, which are further distances than those in Sa-srtA (5.0 Å, 4.9 Å, and 9.5 Å) and in Sp-srtA (6.7 Å, 4.7 Å, and 10.5 Å) (Figure 7). This observation implies that these three residues are very flexible and can accommodate more space,
which may enable the processing of S. pneumoniae TIGR4 sortase B, sortase C and sortase D or other peptide substrates.

Using a transpeptidation activity assay, quercetin was identified as an effective inhibitor of S. pneumoniae sortA by inhibiting Spn-sortA transpeptidase activity. Furthermore, quercetin treatment reduced pneumococcal biofilm formation. Finally, when sialic acid is provided, quercetin is no longer able to inhibit pneumococcal biofilm formation. These results indicate that the small molecule quercetin impairs pneumococcal biofilm formation by directly blocking the anchoring of pneumococcal NanA and indirectly reducing sialic acid production. NanA and biofilm formation are required for pneumococcal colonisation and infection of the upper and lower respiratory tract, respectively. A NanA mutant is cleared from the nasopharynx, trachea, and lungs within 12 hours post-infection and is unable to persist in the blood beyond 48 hours post-infection in vivo. Biofilm formation facilitates the ability of S. pneumoniae to evade complement immunity and phagocytosis by diverting alternative complement pathway activation through a PspC-mediated mechanism. Additionally, Trappetti et al proved that sialic acid is a pivotal signal for the pneumococcal biofilm formation, colonisation, and host invasion.

Molecular modelling simulation analysis has revealed the engagement of quercetin with the channel of Spn-sortA, where the substrate binds to the protein, hinders the recognition of Spn-sortA and its substrate. Resides Leu113 or Leu118 in Spn-sortA are critical for such engagement, as validated by mutational analysis. Our results provide evidence that quercetin is a promising inhibitor for Spn-sortA transpeptidase activity by directly occupying the substrate binding region of this enzyme protein. Thus, quercetin is a potent small-molecule antibiotic that can fight the pneumococcal infection by specially targeting sortA.

ACKNOWLEDGEMENTS

This work was supported by the National Key R & D Program of China (2017YFD0501500) and the National Natural Science Foundation of China (grant 31602109).

CONFLICT OF INTEREST

The authors declare no competing financial interests.

ORCID

Jianfeng Wang http://orcid.org/0000-0001-8311-0894
Xuming Deng http://orcid.org/0000-0001-6411-1074

REFERENCES

1. Rudan I, O’Brien KL, Nair H, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Global Health. 2013;3:010401.
2. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-1322.
3. Bogaert D, Belkum AV, Sluijter M, et al.Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet. 2004;363:1871-1872.
4. Parker D, Soong G, Planet P, Brower J, Ratner AJ, Prince A. The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation. Infect Immun. 2009;77:3722.
5. Trappetti C, Radioglu A, Carter M, et al. Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host. J Infect Dis. 2009;199:1497-1505.
6. Mazmanian SK, Liu G, Ton-That H, Schneewind O. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science. 1999;285:760.
7. Zong Y, Bice TW, Tonthat H, Schneewind O, Narayana SV. Crystal structures of Staphylococcus aureus sortase A and its substrate complex. J Biol Chem. 2004;279:31383-31389.
8. Zong Y, Mazmanian SK, Schneewind O, Narayana SV. The structure of sortase B, a cysteine transpeptidase that tethers surface protein to the Staphylococcus aureus cell wall. Structure. 2004;12:105.
9. Ton-That H, Mazmanian SK, Allsne L, Schneewind O. Anchoring of surface proteins to the cell wall of Staphylococcus aureus - Cysteine 184 and histidine 120 of sortase form a thiolate-imidazolium ion pair for catalysis. J Biol Chem. 2004;279:37763-37770.
10. Paterson GK, Mitchell TJ. The role of Streptococcus pneumoniae sortase A in colonisation and pathogenesis. Microbes Infect. 2006;8:145-153.
11. Hava DL, Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol. 2002;45:1389.
12. Chen S, Paterson GK, Tong HH, Mitchell TJ, DeMaria TF. Sortase A contributes to pneumococcal nasopharyngeal colonization in the chinchilla model. FEMS Microbiol Lett. 2005;253:151-154.
13. Gianfaldoni C, Maccari S, Pancotto L, et al. Sortase A confers protec- tion of China (grant 31602109).

ORCID

Jianfeng Wang http://orcid.org/0000-0001-8311-0894
Xuming Deng http://orcid.org/0000-0001-6411-1074
24. Wang J, Zhou X, Liu S, et al. Morin hydrate attenuates Staphylococcus aureus virulence by inhibiting the self-assembly of α-hemolysin. *J Appl Microbiol.* 2015;118:753-763.

25. Shak JR, Ludewick HP, Howery KE, et al. Novel role for the Streptococcus pneumoniae toxin pneumolysin in the assembly of biofilms. *MBio.* 2013;4:e00655.

26. Trappetti C, Potter AJ, Paton AW, Oggioni MR, Paton JC. LuxS mediates iron-dependent biofilm formation, competence, and fratricide in *Streptococcus* aureus. *Infect Immun.* 2011;79:4550-4558.

27. Liu HH, Tomasz A. Penicillin tolerance in multiply drug-resistant natural isolates of *Streptococcus pneumoniae*. *Infect Immun.* 2011;79:4550-4558.

28. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant *Streptococcus pneumoniae* from the cerebrospinal fluid of a patient who developed recrudescent meningitis. *J Infect Dis.* 2000;181:369-373.

29. Qiu J, Niu X, Dong J, et al. Baicalin protects mice from Staphylococcus aureus pneumonia via inhibition of the cytolytic activity of α-hemolysin. *J Infect Dis.* 2012;206:292.

30. Wang J, Qiu J, Tan W, et al. Fisetin inhibits *Listeria monocytogenes* virulence by interfering with the oligomerization of listeriolysin O. *J Infect Dis.* 2015;211:1376.

31. Mazmanian SK, Liu G, Jensen ER, Lenoy E, Schneewind O. Staphylococcus aureus sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections. *Proc Natl Acad Sci USA.* 2000;97:5510-5515.

32. Wang C, Li M, Feng Y, et al. The involvement of sortase A in high virulence of STSS-causing *Streptococcus suis* serotype 2. *Arch Microbiol.* 2009;191:23.

33. Race PR, Bentley ML, Melvin JA, et al. Crystal structure of Staphylococcus pyogenes sortase A: implications for sortase mechanism. *J Biol Chem.* 2009;284:6924-6933.

34. Weiner EM, Robson S, Marohn M, Clubb RT. The sortase A enzyme that attaches proteins to the cell wall of *Bacillus anthracis* contains an unusual active site architecture. *J Biol Chem.* 2010;285:23433-23443.

35. Chambers CJ, Roberts AK, Shone CC, Acharya KR. Structure and function of a *Clostridium difficile* sortase enzyme. *Sci Rep.* 2015;5:9449.

36. Kang SS, Kim JG, Lee TH, Oh KB. Flavonols inhibit sortases and sortase-mediated Staphylococcus aureus clumping to fibrinogen. *Biomed Res Int.* 2013;2013:946263.

37. Zhang J, Liu H, Zhu K, et al. Antiinfective therapy with a small molecule inhibitor of *Staphylococcus aureus* sortase. *Proc Natl Acad Sci USA.* 2014;111:13517-13522.

38. Ping H, Ping H, Su Yun Z, Qian L, Wei Min C. Morin inhibits sortase A and subsequent biofilm formation in *Streptococcus mutans*. *Curr Microbiol.* 2014;68:52-57.

39. Manco S, Hernon F, Yesilkaya H, Paton JC, Andrew PW, Kadioglu A. Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis. *Infect Immun.* 2006;74:4014-4020.

40. Domenech M, Ramossevillano E, García E, Moscoso M, Yuste J. Biofilm formation avoids complement immunity and phagocytosis of *Streptococcus pneumoniae*. *Infect Immun.* 2013;81:2606.

**How to cite this article:** Wang J, Song M, Pan J, et al. Quercetin impairs *Streptococcus pneumoniae* biofilm formation by inhibiting sortase A activity. *J Cell Mol Med.* 2018;22:6228–6237. [https://doi.org/10.1111/jcmm.13910](https://doi.org/10.1111/jcmm.13910)